A new once-a-day inhaler by the name of Relvar Ellipta will be available for asthma sufferers in Britain. The inhaler combines a daily dose of steroid, which is used to reduce inflammation in the airways, with a new type of long-lasting beta2 agonist, which focuses on dilation.
The product speaks to a need for simplicity, as studies show that many asthma patients find it difficult to manage two separate inhalers. The long-lasting drug will provide relief throughout the entire day, although some users may have to carry a blue inhaler for "immediate relief."
The drug is not limited to those with asthma however; it can also be used to combat a long list of respiratory illnesses, such as COPD.
Simplified Asthma Inhalers
This Once-a-Day Inhaler Provides 24-Hour Relief
Trend Themes
1. Simplified Asthma Treatment - The development of a once-a-day inhaler for asthma sufferers addresses the need for simpler treatment options.
2. Combination Inhalers - The combination of a steroid and a long-lasting beta2 agonist in a single inhaler offers convenience and better management of respiratory illnesses.
3. Expanded Applications for Inhalers - The use of the new inhaler beyond asthma treatment opens up opportunities for treating various respiratory illnesses such as COPD.
Industry Implications
1. Pharmaceuticals - The development and manufacturing of simplified inhalers provide opportunities for pharmaceutical companies to enhance asthma and respiratory illness treatments.
2. Healthcare - The introduction of once-a-day inhalers in healthcare facilitates improved management of asthma and respiratory conditions, potentially leading to better patient outcomes.
3. Medical Devices - The innovation in inhaler technology creates disruptive opportunities for medical device companies to create more efficient and user-friendly respiratory treatment devices.